Here, we explored the effects of the GLP-1 analogue liraglutide on liver fat content and serum FGF21 levels in newly diagnosed overweight patients with T2DM and NAFLD. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.